In our study, we confirm that IL-36α levels are present at low levels in patients in the reference group and in patients with ovarian cancer stage G1 and G2, which in these cases may indicate an anti-tumor role for this interleukin. This evidence concerns the gene IL36A and ovarian carcinoma.